Leukemic blasts in transformed JAK2-V617F–positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation.

Alexandre Theocharides(University Hospital of Basel), Marjorie Boissinot(Inserm), François Girodon(CHU Dijon Bourgogne), Richard Garand(Centre Hospitalier Universitaire de Nantes), Soon-Siong Teo(University Hospital of Basel), Éric Lippert(Centre Hospitalier Universitaire de Bordeaux), Pascaline Talmant(Centre Hospitalier Universitaire de Nantes), André Tichelli(University Hospital of Basel), Sylvie Hermouet(Inserm), Radek C. Skoda(University Hospital of Basel)
Blood
March 15, 2007
Cited by 320

Abstract

To study the role of the JAK2-V617F mutation in leukemic transformation, we examined 27 patients with myeloproliferative disorders (MPDs) who transformed to acute myeloid leukemia (AML). At MPD diagnosis, JAK2-V617F was detectable in 17 of 27 patients. Surprisingly, only 5 of 17 patients developed JAK2-V617F-positive AML, whereas 9 of 17 patients transformed to JAK2-V617F-negative AML. Microsatellite analysis in a female patient showed that mitotic recombination was not responsible for the transition from JAK2-V617F-positive MPD to JAK2-V617F-negative AML, and clonality determined by the MPP1 polymorphism demonstrated that the granulocytes and leukemic blasts inactivated the same parental X chromosome. In a second patient positive for JAK2-V617F at transformation, but with JAK2-V617F-negative leukemic blasts, we found del(11q) in all cells examined, suggesting a common clonal origin of MPD and AML. We conclude that JAK2-V617F-positive MPD frequently yields JAK2-V617F-negative AML, and transformation of a common JAK2-V617F-negative ancestor represents a possible mechanism.


Related Papers

No related papers found

Powered by citation graph analysis